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Introduction
The evaluation of intranodular hemodynamics is
extremely important in the diagnosis of hepatic
tumors, because the pathologic findings of hepatic
tumors are closely related to intranodular hemo-
dynamics. B-mode ultrasound (US) is useful in the
screening of liver diseases, but it cannot demonstrate
tumor vascularity.
Color Doppler imaging reveals arterial and venous
blood flow such as basket pattern flow or “spot”
pattern flow for hepatic tumor differentiation [1,2].
However, color Doppler US cannot always detect
pulsatile flow in all hepatocellular carcinomas (HCCs).
The reasons for this are: (1) color Doppler US cannot
detect flows that are perpendicular to the sound
field [3]; and (2) the technique uses an estimate of the
mean Doppler frequency shift at a particular position.
In contrast, power Doppler imaging measures the
Doppler energy, which is based on the integrated
power of the Doppler signal instead of its mean
Doppler frequency shift. Previous studies have docu-
mented power Doppler US as more sensitive in 
the depiction of blood vessels than color Doppler
imaging [3,4]. These techniques are noninvasive
and inexpensive; however, they have some intrinsic
limitations including a low sensitivity for detecting
the microflow in nodules.
Efforts have been made to improve both US
instrumentation and contrast agents to detect slow
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flow in tumors with greater sensitivity [5,6]. US with
intra-arterial carbon dioxide microbubble contrast
agents have enabled the investigation of intratu-
moral hemodynamics, and the differential diagnosis
of hepatic tumors has become easier [7]. Contrast-
enhanced US using the intravenous injection of
Levovist uses the nonlinear backscatter property of
the resonant or disrupted microbubbles. Contrast-
enhanced US using Levovist has allowed microflow
imaging of nodules to some extent and has elimi-
nated clutter signals. However, Levovist bubbles are
easily collapsed by US emission because of their
fragility. Therefore, Levovist-enhanced harmonic US
is basically obtained intermittently, and real-time
images are obtained only within a short period of
time at an early vascular phase, and Kupffer imaging
in the postvascular phase can be performed only by
a single sweep scan of the liver.
With the development of second-generation
contrast agents, such as Sonazoid, which are com-
posed of a hard shell containing bubbles within,
contrast-enhanced harmonic US has entered a new
era. Sonazoid produces stable nonlinear oscillations
in the low-power acoustic field (i.e. low mechanical
index) and produces enhanced images of the phase-
inversion harmonic signals in real time. This contrast
agent provides detailed perfusion features of the
microvascular bed of the liver parenchyma and
tumor during the vascular phase. Moreover, Kupffer
imaging in the postvascular phase, which is stable
for at least 60 minutes post-injection and tolerable
for multiple scanning, can be obtained with low
acoustic power, because Sonazoid microbubbles
are phagocytosed by Kupffer cells [8].
In this article, the value of contrast-enhanced
harmonic US using Sonazoid for the differential
diagnosis of liver tumors and its usefulness in the
treatment of HCC will be reviewed.
US Contrast Agent
Sonazoid (Daiichi-Sankyo, Tokyo, Japan; GE Health-
care, Milwaukee, WI, USA) is a second-generation
microbubble agent for US. Sonazoid consists of
perfluorobutane microbubbles with a median diam-
eter of 2–3µm [9,10]. Sonazoid is reconstituted with
2mL of sterile water for injection. The recommended
clinical dose for imaging liver lesions is 0.015 mL
encapsulated gas per kilogram of body weight; how-
ever, a dose of 0.010 mL/kg of Sonazoid is adequate
for routine clinical use. Sonazoid is injected as a bolus
at 1 mL/s via a 22-gauge cannula placed in the
antecubital vein, and flushed with 10 mL of normal
saline.
Imaging
In our institution, before a contrast-enhanced US
study, B-mode US scans are usually obtained using
a GE LOGIQ 7 (GE Medical Systems, Milwaukee, WI,
USA) with a 4-MHz convex transducer or a 6.5-MHz
transducer. The acoustic power of contrast-enhanced
US is set to the default settings with a mechanical
index of 0.2; the dynamic range is fixed at 60–65dB.
A single focus point is set at a depth of 10 cm.
After injection of Sonazoid, the patient is request-
ed to hold his/her breath when the first microbubble
signal appears in the liver parenchyma. The images
of the ideal scanning plane are displayed in real
time for all phases. The vascular findings on phase-
inversion harmonic US are shown as tumor vessel
flow in the early vascular phase (about 15–40 sec-
onds after the injection of Sonazoid). The real-time
replenishing images are obtained during the early
vascular phase (less than 2 minutes after the injection
of Sonazoid) using burst acoustic power, which is 
a method combining multiple high frequency and
broadband detection pulses with a separate burst.
Parenchymal findings are obtained as Kupffer im-
aging in the postvascular phase at least 10 minutes
after the intravenous injection of Sonazoid.
Data Analysis
The images are stored as a cine clip with GE  Medical
Systems exclusive raw data format files in a LOGIQ
7 computer. The cine clip images of B-mode and
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contrast-enhanced US are played back, and by
reviewing these images, the intratumoral hemody-
namics can be precisely classified into seven patterns.
The intratumoral vascularity on contrast-enhanced
US can be assessed as hyperperfusion, isoperfusion,
hyperperfusion in hypoperfusion (nodule-in-nodule
type) or hypoperfusion, by comparing the staining
patterns of the intratumoral vessels and parenchyma
with those of the surrounding liver parenchyma.
Differential Diagnosis of Hepatic
Tumors
Enhancement patterns
The intranodular hemodynamic patterns of nodular
hepatic lesions can be classified as follows (Fig. 1):
1. Type 1 (HCC pattern): Abundant tumor vessels
appearing as basket-like or irregular branched
images from the periphery penetrating the center,
followed by dense tumor staining in the early
vascular phase and fast washout in the late vas-
cular phase with complete Kupffer defect.
2. Type 2 (metastasis pattern): Straight tumor vessels
in the marginal and central areas with peripheral
parenchymal staining or rim-like enhancement
with complete Kupffer defect in the postvascular
phase.
3. Type 3 (hemangioma pattern): Globular enhance-
ment or a cotton wool-like imaging with a
gradual fill-in over time, which continues for 
5 or 10 minutes.
4. Type 4 (dysplastic nodule pattern): No tumor
vessels and positive portal perfusion without arte-
rial perfusion with real-time scanning in the early
vascular phase and no apparent Kupffer defect.
5. Type 5 (focal nodular hyperplasia pattern):
Centrifugal spoke-wheel arterial supply with
continuing dense parenchymal staining in the
vascular phase with no Kupffer defect.
Fig. 1. Schematic representation of the intranodular hemodynamic patterns of hepatic tumors in the early vascular, late vascular
and postvascular phases.
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6. Type 6 (atypical pattern): Various tumor vessels
and different parenchymal perfusions from those
described above.
7. Type 7 (hypovascular pattern): No tumor ves-
sels and no parenchymal perfusion in any phase.
HCC
In our study, intranodular vascularity was detected
in 99.4% (176/177) of HCCs on contrast-enhanced
harmonic US. In the remaining 0.6% (1/177) of
HCCs, no vascular signal was detected. In contrast,
98.9% (175/177) of HCCs showed hyperperfusion
or isoperfusion on dynamic computed tomography
(CT) [10].
One hundred and seventy-one of 176 HCCs
(97.2%) were classified as type 1 (HCC perfusion
pattern; Figs. 1 and 2) on contrast-enhanced har-
monic US, 2.3% (4/176) of HCCs were classified as
having the atypical perfusion pattern (type 6), and
0.6% (1/176) of HCCs showed the hypoperfusion
pattern (type 7). Twenty of 171 (11.7%) of type 1
perfusion nodules had small tumor vessels; however,
dense intranodular perfusion was present, followed
by fast washout in the late vascular phase. Sixty-nine
of 171 (40.3%) type 1 HCC pattern showed mod-
erate tumor vessels, while 48.0% (82/171) showed
abundant tumor vessels in the early vascular phase on
contrast-enhanced harmonic US. In 2.3% of type 1
HCC pattern (4/171), tumor parenchymal staining
was detected in only small parts of the nodule. Of
the 171 type 1 perfusion-type HCCs, 2.3% (4/171)
showed partial perfusion defects and 97.7% (147/
171) showed complete perfusion defects in the
Kupffer phase.
Most of the HCCs showed HCC perfusion patterns
on contrast-enhanced harmonic US. The sensitivity
and specificity of the HCC pattern were 96.6% (171/
177) and 94.4% (68/72), respectively. The positive
and negative predictive values of this pattern were
97.7% (171/175) and 91.9% (68/74), respectively.
On angiography, carbon dioxide sonographic
angiography and CT arteriography, HCC shows
A B C D
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Fig. 2. (A) Dynamic computed tomography in the arterial phase clearly shows high density nodules in segment 4. (B) Dynamic
computed tomography in the portal venous phase clearly shows low density nodules in segment 4. (C) T2-weighted magnetic resonance
imaging clearly shows high density nodules. (D) Digital subtraction angiography clearly shows tumor stain, compatible with hepatocellular
carcinoma. (E) B-mode ultrasound shows a hypoechoic mass in segment 4. (F) Hyperperfusion mass is evident using Sonazoid-enhanced
ultrasound. (G) Kupffer defect is evident in the postvascular phase of Sonazoid-enhanced ultrasound.
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hypervascularity with an arterial supply and dense
tumor perfusion [7,11–13]. In Sonazoid-enhanced
US, Sonazoid-enhanced harmonic US revealed that
96.6% of HCCs (171/177) showed an arterial supply
from the periphery, homogeneous or heterogeneous
dense hyperperfusion, and fast washout with a clear
Kupffer defect. On contrast-enhanced harmonic US,
the formation of homogeneous or heterogeneous
staining in the early vascular phase and the formation
of washout in the late vascular phase were similar to
dynamic CT. Evaluating the perfusion images in all
three phases may allow precise assessment of the
intranodular hemodynamic features of HCCs [9].
Metastasis
In 37 nodules of 42 metastases, contrast-enhanced
US showed linear tumor vessels and marginal rim-
like parenchymal staining. Although the other five
metastases had small tumor vessels and weak pa-
renchymal perfusion, all metastases showed clear
Kupffer defects in the postvascular phase [9]. Most
of the metastases showed a type 2 perfusion pattern
(Figs. 1, 3 and 4) on contrast-enhanced US. The
sensitivity and specificity of the metastasis pattern
were 88.1% (37/42) and 100% (207/207), respec-
tively. The positive and negative predictive values
of this pattern were 100% (37/37) and 97.6% (207/
212), respectively.
Using contrast-enhanced harmonic US, 88.1%
(37/42) of metastases were shown to have periph-
eral linear tumor vessels with rim-like enhancement
between the non-enhanced portion of the lesion
and the enhanced surrounding parenchyma. This
perfusion pattern was not seen in other liver tumors
and is similar to the pattern obtained with dynamic
CT or superparamagnetic iron oxide-enhanced mag-
netic resonance imaging. All metastases were dem-
onstrated as clear defects in the Kupffer phase [10].
Only four nodules of metastasis showed an atypical
A B
Fig. 3. Metastasis from pancreatic cancer. (A) Peripheral hypervascular pattern was clearly demonstrated in the vascular phase of
contrast-enhanced ultrasound. (B) A clear defect is evident in the Kupffer phase of contrast-enhanced ultrasound.
Fig. 4. Metastasis from pancreatic cancer. Sweep scan in the
Kupffer phase of contrast-enhanced ultrasound clearly shows
multiple metastases, many more than detected by multidetector
computed tomography.
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pattern which may be caused by different charac-
teristics of the primary cancer.
Hemangioma
On contrast-enhanced harmonic US, all heman-
giomas revealed hypervascularity, and the type 3
perfusion patterns (Figs. 1 and 4) of hemangioma
were present in 18 nodules. Gradual fill-in and glob-
ular enhancement in the late vascular phase per-
sisted until the postvascular phase. The sensitivity
and specificity of the hemangioma pattern were
90.0% (18/20) and 99.6% (228/229), respectively.
The positive and negative predictive values of this
pattern were 94.7% (18/19) and 99.1% (228/
230), respectively [9]. Two hemangiomas showed
tumor vessels and dense parenchymal pooling in
the early vascular phase, which was difficult to dis-
tinguish from the hemodynamic pattern of HCC.
However, the intranodular pooling continued to the
late vascular phase, leading to a correct diagnosis
of hemangioma.
On contrast-enhanced harmonic US, typical
spotty pooling in the vascular phase followed by
globular or cotton wool pooling was detected in
the hemangiomas. This perfusion pattern was not
seen in any other hepatic tumors. Small-sized
hemangiomas occasionally showed early tumor
vessels and parenchymal perfusion in the vascular
phase. However, this intratumoral perfusion con-
tinued to the Kupffer phase, leading to the correct
diagnosis of hemangioma.
Dysplastic nodules
Contrast-enhanced US showed no tumor vessels
and portal perfusion without arterial perfusion in
all of the five dysplastic nodules in the early vascu-
lar phase. In the late vascular and postvascular
phases, contrast-enhanced harmonic US showed
isoperfusion in four tumors and hyperperfusion 
in one tumor. The remaining nodule showed no
tumor vessels and a hypovascular perfusion in the
three phases. The sensitivity and specificity of the
type 4 pattern (Figs. 1 and 5) were 83.3% (5/6)
and 100% (244/244), respectively. The positive
and negative predictive values of this pattern were
100% (5/5) and 99.6% (244/245), respectively.
A B C
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Fig. 5. Hemangioma. (A) Hypoechoic nodule detected on B-mode ultrasound. (B) Peripheral globular enhancement demonstrated
by contrast-enhanced ultrasound. (C) Gradual filling over time was observed. (D) Spotty pooling was observed in the late vascular
phase. (E) Globular enhancement pattern confirmed this nodule to be hemangioma. (F) Defect is seen in the Kupffer phase.
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Many studies have described the hemodynamic
characteristics of dysplastic nodules as portal supply
and arterial hypovascularity [4,13–15]. Sonazoid-
enhanced US demonstrated five dysplastic nodules
with arterial hypovascularity and portal supply in the
early vascular phase. The positive uptake in the Kupf-
fer phase might also have been attributed to the pres-
ence of Kupffer cells in the nodules. The diagnostic
criteria of the dysplastic nodules are a high specificity
and positive predictive value but a low sensitivity.
Focal nodular hyperplasia
All four focal nodular hyperplasias (FNHs) showed
a central arterial supply with a centrifugal radiating
flow to the periphery (spoke-wheel pattern) and
dense parenchymal staining in the late vascular
phase (type 5) with no Kupffer defect (Figs. 1 and 6).
The sensitivity and specificity of the FNH pattern
were 100% (4/4) and 100% (4/4), respectively.
On dynamic CT, the spoke-wheel pattern was not
detected in any of the four FNHs, and only hyperper-
fusion was observed. Previous studies have reported
that the spoke-wheel appearance is a pathognomonic
finding of FNHs [7,16]. In our preliminary experi-
ence, all FNHs had the typical arterial supply of the
spoke-wheel appearance on contrast-enhanced US.
The sensitivity and specificity of the FNH pattern
were both 100% [9]. Contrast-enhanced harmonic
US could directly show the depiction of tumor ves-
sels and was superior to dynamic CT or Levovist-
enhanced US for the diagnosis of FNHs.
Role of Sonazoid-enhanced US in the
Diagnosis of Hepatic Tumors
Various gases or shells have been studied for their
use as sonographic contrast agents [7–10,17], and
A B C
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Fig. 6. Focal nodular hyperplasia. (A) B-mode ultrasound shows
an isoechoic nodule (arrows). (B, C) On contrast-enhanced ultra-
sound, central arterial supply (arrowheads) with a centrifugal
radiating flow to the periphery is present within the nodule
(arrows) in the early vascular phase. (D) Contrast-enhanced
ultrasound accompanied by dense parenchymal staining (arrows)
in the early vascular phase. (E) The tumor is shown as isoperfusion
(arrows) on the grayscale background in the Kupffer phase. (F)
Hepatic angiography shows central arterial supply with a cen-
trifugal radiating flow to the periphery. (G) Dynamic computed
tomography shows a hypervascular tumor.
contrast-enhanced harmonic US using various
contrast agents has been possible [6,11,18–20].
Sonazoid has been licensed since January 2007 for
exclusive use in Japan. Gas-carrier contrast agents
consist of microbubbles which are small enough to
pass through the pulmonary circulation, and these
microbubbles are sufficiently pressure-stable to cir-
culate through the left ventricle after intravenous
administration. Because Sonazoid microbubbles are
phagocytosed by Kupffer cells [8], Kupffer imaging,
which is extremely stable and tolerable for multiple
scanning at least up to 60 minutes in the postvas-
cular phase, is feasible. Once Sonazoid is adminis-
tered to the patient via a vein, both blood vessel
imaging and liver parenchymal imaging (Kupffer
imaging) can be obtained. These properties are
completely different from commercially available
second-generation, contrast-enhancing agents in
other countries, such as SonoVue or Definity.
Levovist-enhanced harmonic US can display
images under high acoustic power, and only inter-
mittent imaging is obtained. However, Sonazoid-
enhanced harmonic US displays images under a
low acoustic power, producing much clearer real-
time images. Therefore, it is much easier to scan
the intratumoral hemodynamics repeatedly using
Sonazoid-enhanced harmonic US.
Compared with dynamic CT, Sonazoid-enhanced
US requires no radiation exposure and a smaller
amount of contrast agent. Although there is one
contraindication for patients who are allergic to eggs,
patients with renal dysfunction or with iodine allergy
can also be examined using this technique, unlike
CT. In addition, Sonazoid is taken up by Kupffer
cells, which is different from other contrast agents,
and the analysis of Kupffer function provides essential
information compared with other contrast agents
[8,20].
D’Onofrio et al [19] reported SonoVue-enhanced
US detected hepatic malignancy as defects on the
sinusoidal phase with a sensitivity of 85%, speci-
ficity of 88%, positive predictive value of 92%, and
negative predictive value of 77%. In our experience,
Sonazoid-enhanced harmonic US detected hepatic
malignancy as defects on the sinusoidal phase with
a sensitivity of 95% (208/219), specificity of 93.3%
(28/30), positive predictive value of 99% (208/210),
and negative predictive value of 97.4% (38/39) [10].
These favorable results can be attributed to the
extremely stable features of Kupffer imaging.
The evaluation of deeply located nodules was
reported to be difficult with contrast-enhanced
harmonic US using Levovist [6,12,18]. In our expe-
rience with Sonazoid, 8.4% (21/249) of hepatic
tumors were located 10 cm beneath the skin sur-
face. However, contrast-enhanced US with Sonazoid
allowed sufficient imaging to evaluate the intratu-
moral vascularity, which is another favorable aspect
compared with Levovist.
Innovation of Defect Reperfusion
Imaging (Dual Phase Fusion Imaging)
We recently developed “defect reperfusion imaging”
using the properties of very stable Kupffer images
and real-time fine blood flow images obtained with
Sonazoid for typical HCC, which is depicted by CT
but not visualized by B-mode US. This method is a
breakthrough for accurate localization and treatment
guidance (Fig. 6) [21].
After the intravenous injection of Sonazoid (0.01
mL/kg), early stains were observed in the vascular
phase, and the presence or absence of defects was
determined in the Kupffer phase 10–60 minutes after
injection. Subsequently, the probe was applied to
the area showing a defect in the Kupffer phase,
Sonazoid (0.01 mL/kg) was additionally injected,
and whether arterial blood entered the defective
area was determined (defect re-injection method).
When the presence of arterial vascularity in the
Kupffer defect was regarded as a “reperfusion sign
(+)”, the detection rate for typical HCC was almost
100% (Figs. 7 and 8). In addition, for nodules which
could not be visualized by B-mode US, Sonazoid
was re-injected in the postvascular phase, where
clear defects could be detected, and not in the
vascular phase where arterial blood flow could not
be detected as localization was not possible. After
this re-injection, a clear stain could be detected in
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the Kupffer defect (positive defect reperfusion sign),
and radiofrequency ablation under the guidance of
Sonazoid-enhanced US was possible.
With this method, nodules which could not 
be visualized by B-mode US were first detected as
defects on Kupffer images in the stable Kupffer phase,
and subsequently, whether or not nodules show-
ing Kupffer defects themselves had arterial blood
flow were determined by the re-injection test. This
method may be a breakthrough in diagnostic imag-
ing (Figs. 7 and 8) [21]. This contrast-enhanced US
technique requires no special apparatus or analy-
sis, and is a result of a change in the “concept of
contrast-enhanced US”. For the typical CT image
(so-called “early enhancement with late wash-out”
nodules), defects were first detected in the Kupffer
phase, and subsequently, perfusion in the defects was
demonstrated by the re-injection test (visualization
of “staining within the Kupffer defects”, which is a
reverse phenomenon of “early enhancement with
late washout”). The introduction of this innovative
idea allowed almost 100% identification of lesions
which showed typical CT images and were not
visualized on B-mode US images. If the reperfusion
test showed no enhancement of a Kupffer defect,
this defect would differ from the nodule detected
by CT. Therefore, this method should be an epoch-
making treatment aid for HCC, which facilitates
M. Kudo, K. Hatanaka, K. Maekawa
138 J Med Ultrasound 2008 • Vol 16 • No 2
A B
Fig. 8. Local recurring nodule in which defect reperfusion imaging was useful in its localization. (A) Low echoic nodule identified
by Kupffer phase imaging, next to the previously ablated lesion. (B) Re-injection of Sonazoid clearly shows arterial vascularity in the
Kupffer defect area.
Enhancement (−)Defect
Defect reperfusion sign (+)
→ typical HCC
Enhancement (+)
Defect reperfusion sign (−)
→ non-typical HCC
Defect
(Regenerative nodule,
post-ablated nodule)
Defect reinjection testKupffer phase
Fig. 7. Usefulness of defect reperfusion imaging in the sonography of ill-defined nodule. HCC = hepatocellular carcinoma.
Contrast-enhanced US Using Sonazoid for Liver Tumors
139J Med Ultrasound 2008 • Vol 16 • No 2
needle insertion guidance. In addition, this “defect
reperfusion imaging” has wide possibilities, appli-
cable for screening HCC in coarse liver parenchyma,
the localization of local recurrence after treatment,
and needle insertion under the guidance of contrast-
enhanced US.
Conclusion
Sonazoid-enhanced harmonic US is a superb tech-
nique for the noninvasive characterization of hepatic
tumors, based on the sensitive and specific vascular
and Kupffer phase characteristic imaging pattern for
each hepatic tumor. It is also useful in treatment
guidance for HCCs, especially HCC nodules which
are not detected by B-mode US but demonstrated
on dynamic CT.
References
1. Tanaka S, Kitamura T, Fujita M, et al. Color Doppler
flow imaging of liver tumors. AJR Am J Roentgenol
1990;154:509–14.
2. Tanaka S, Kitamura T, Fujita M, et al. Small hepato-
cellular carcinoma: differentiation from adenomatous
hyperplastic nodule with color Doppler flow imaging.
Radiology 1992;182:161–5.
3. Rubin JM, Bude RO, Carson PL, et al. Power Doppler
US: a potentially useful alternative to mean frequency-
based color Doppler US. Radiology 1994;190:853–6.
4. Koito K, Namieno T, Morita K. Differential diagnosis
of small hepatocellular carcinoma and adenomatous
hyperplasia with power Doppler sonography. AJR Am
J Roentgenol 1998;170:157–60.
5. Ding H, Kudo M, Maekawa K, et al. Detection of
tumor parenchymal blood flow in hepatic tumors:
value of second harmonic imaging with a galactose-
based contrast agent. Hepatol Res 2001;21:242–51.
6. Ding H, Kudo M, Onda H, et al. Hepatocellular car-
cinoma: depiction of tumor parenchymal flow with
intermittent harmonic power Doppler US during the
early arterial phase in dual-display mode. Radiology
2001;220:349–56.
7. Kudo M, Tomita S, Tochio H, et al. Sonography 
with intraarterial infusion of carbon dioxide microbub-
bles (sonographic angiography): value in differential 
diagnosis of hepatic tumors. AJR Am J Roentgenol
1992;158:65–74.
8. Yanagisawa K, Moriyasu F, Miyahara T, et al. Phagocy-
tosis of ultrasound contrast agent microbubbles by
Kupffer cells. Ultrasound Med Biol 2007;33:318–25.
9. Hatanaka K, Kudo M, Minami Y, et al. Differential diag-
nosis of hepatic tumors: value of contrast-enhanced
harmonic sonography using the newly developed con-
trast agent, Sonazoid. Intervirology 2008 (In press).
10. Sontum PC, Ostensen J, Dyrstad K, et al. Acoustic
properties of NC100100 and their relation with the
microbubble size distribution. Invest Radiol 1999;34:
268–75.
11. Kudo M. Morphological diagnosis of hepatocellular
carcinoma: special emphasis on intranodular hemo-
dynamic imaging. Hepatogastroenterology 1998;45:
1226–31.
12. Wen YL, Kudo M, Zheng RQ, et al. Characterization
of hepatic tumors: value of contrast-enhanced coded
phase inversion harmonic US. AJR Am J Roentgenol
2004;182:1019–26.
13. Matsui O, Kadoya M, Kameyama T, et al. Benign
and malignant nodules in cirrhotic livers: distinction
based on blood supply. Radiology 1991;178:493–7.
14. Takayama T, Makuuchi M, Hirohashi S, et al. Malig-
nant transformation of adenomatous hyperplasia to
hepatocellular carcinoma. Lancet 1990;336:1150–3.
15. Kudo M. Imaging diagnosis of hepatocellular carci-
noma and premalignant/borderline lesions. Semin
Liver Dis 1999;19:297–309.
16. Wanless IR, Mawdsley C, Adams R. On the patho-
genesis of focal nodular hyperplasia of the liver.
Hepatology 1985;5:1194–200.
17. Maresca G, Summaria V, Colagrande C, et al. New
prospects for ultrasound contrast agents. Eur J Radiol
1998;27(Suppl 2):S171–8.
18. Isozaki T, Numata K, Kiba T, et al. Differential diagnosis
of hepatic tumors by using contrast enhancement
patterns at US. Radiology 2003;229:798–805.
19. D’Onofrio M, Martone E, Faccioli N, et al. Focal liver
lesions: sinusoidal phase of CEUS. Abdom Imaging
2006;31:529–36.
20. Kudo M, Okanoue T; for Clinical Practice Manual of
HCC Expert Panel. Management of hepatocellular
carcinoma in Japan: consensus-based clinical practice
manual proposed by the Japan Society of Hepatology.
Oncology 2007;72(Suppl 1):2–15.
21. Kudo M, Hatanaka K, Chung H, et al. A proposal of
novel treatment-assist technique for hepatocellular
carcinoma in the Sonazoid-enhanced ultrasonography:
value of defect re-perfusion imaging. Kanzo 2007;48:
299–301. [In Japanese]
